Docetaxel With or Without PI-88 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Diagnosis of non-small cell lung cancer
• * Stage IIIB or IV disease
• Eligible for second-line docetaxel
• * Disease progression during or after completion of prior first-line therapy comprising radiotherapy and/or platinum-based chemotherapy
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• ECOG 0-1
• Life expectancy
• At least 2 months
• Hematopoietic
• Neutrophil count \> 1,500/mm\^3
• Platelet count \> 100,000/mm\^3
• WBC \> 3,000/mm\^3
• No history of thrombotic thrombocytopenic purpura or other platelet disease
• Hepatic
• Bilirubin normal
• ALT and AST ≤ 2.5 times upper limit of normal (ULN) (1.5 times ULN if alkaline phosphatase \> 2.5 times ULN)
• Alkaline phosphatase ≤ 5 times ULN (unless bone metastases are present)
• PT \< 1.5 times ULN
• Activated PTT normal
• Renal
• Creatinine clearance or glomerular filtration rate \> 50mL/min
• Cardiovascular
• None of the following within the past 3 months:
• * Myocardial infarction
• * Stroke
• * Congestive heart failure
• Immunologic
• No history of immune-mediated thrombocytopenia
• No evidence of anti-heparin antibodies
• No history of allergy and/or hypersensitivity to anti-coagulants or thrombolytic agents, especially heparin
• No history of allergy to polysorbate 80
• No uncontrolled or serious infection within the past 4 weeks
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• Not specified
• Chemotherapy
• See Disease Characteristics
• No prior docetaxel
• Endocrine therapy
• Not specified
• Radiotherapy
• See Disease Characteristics
• More than 3 months since prior radiotherapy to \> 30% of marrow-bearing bone
• Concurrent local palliative radiotherapy allowed
• Surgery
• More than 4 weeks since prior major surgery
• Other
• More than 4 weeks since prior antineoplastic therapy
• More than 2 weeks since prior and no concurrent heparin or low-molecular weight heparin
• More than 4 weeks since prior investigational therapy
• No concurrent aspirin or aspirin-containing medications except low-dose aspirin (≤ 100 mg/day)
• No concurrent nonsteroidal anti-inflammatory drugs except cyclooxygenase-2 inhibitors
• No concurrent warfarin or warfarin-containing medications except low-dose warfarin (≤ 1 mg/day)
• No concurrent antiplatelet drugs, including any of the following:
• * Abciximab
• * Clopidogrel
• * Dipyridamole
• * Ticlopidine
• * Tirofiban
• No concurrent drugs that may inhibit docetaxel metabolism, including any of the following:
• * Cyclosporine
• * Terfenadine
• * Ketoconazole
• * Erythromycin
• * Troleandomycin
• No other concurrent investigational drugs
• No other concurrent antineoplastic therapy